Table 2.

Radiation recall reaction characteristics, single- and multidrug regimens containing cisplatin

Drug regimen	Number of reported cases	Radiation recall reactions	Severity (CTCAE) median (range)	Body site(s)	Mean EQD2 dose (range)	Time range RT to trigger	Time range trigger to RRR
Cisplatin	3	Dermatitis	1 (1–2)	Face, neck, trunk	68 Gy (66–70)	3–12 months	A few minutes–6 hours
Gemcitabine/cisplatin	7	Dermatitis, myositis, proctitis	3 (2–3)	Neck, trunk, shoulder	43 Gy (18–56)	1 months–37 years	1 weeks–3 months
Cisplatin/5-fluorouracil	6	Dermatitis, myositis, mucositis	1 (1–3)	Scalp, oral, neck, trunk, perianal	64 Gy (43–74)	3 weeks–9 years	3 days–3 months
Cisplatin/pemetrexed	4	Dermatitis	2 (1–3)	Scalp, trunk	42 Gy (N.A.)	3–4 weeks	2–5 days
Cisplatin/cytarabine ± rituximab	2	Dermatitis, esophagitis	1 (1)	Thorax	N.A.	3–4 weeks	3–5 days
Paclitaxel/cisplatin	3	Dermatitis	1 (1)	Breast, trunk	56 Gy (50–67)	4–8 months	3 hours–5 days
Cisplatin/doxorubicin ± cyclophosphamide	2	Dermatitis	1 (1–2)	Trunk	N.A.	3 weeks–9 months	3–5 days
Cisplatin/epirubicin ± mitomycin	2	Dermatitis	2 (2)	Head	N.A.	3–26 months	N.A.
Cisplatin/vinorelbine	1	Dermatitis	2 (2)	Trunk	73 Gy (N.A.)	1 week	2 weeks

N.A. not available, CTCAE Common Terminology Criteria for Adverse Events, EQD2 equivalent dose at 2 Gy, RT radiation therapy, RRR radiation recall reaction, Gy Gray